Effectiveness O
of O
chemoprophylaxis O
assessed O
by O
incidence O
of O
secondary O
COVID-19 O
cases O

serum O
albumin O

Time O

2019-ncov O

Symptomatic O
COVID-19 O
infection O
rate O

Prevention B-outcome
of I-outcome
COVID-19 I-outcome

COVID-19 O
diagnosis O

Number O
of O
symptomatic O
COVID-19 O

Frequency O
of O
vaccine O
events O
Frequency O

RT-PCR O
confirmed O
COVID-19 O
infection O

Clinical O

Frequency O
of O
solicited O
local O
reactogenicity O
adverse O

Safety O
indexes O
of O
adverse O
reactions O

Positive O
predicted O

the O
negative O
conversion O
ratio O

Incidence O
of O
onset O

Viral O
nucleic O

viral O
negative-transforming O
time O
30-day O
cause-specific O

Proportion O
of O
COVID-19 O
close O

Length O
of O
hospital O
stay O

Number O

PCL O
PSQI O
FSI O

mood O
assessment O

During O
the O
operation, O

Blood O
routine O
examination O
Chest O

Inccidence O
of O
2019-nCoV O
pneumonia O

SCL-90 O
scale O

Shorten O

cough O
agitation O

novel O
coronavirus O
nucleic O

adverse O
reactions O
7 B-outcome
days I-outcome
post I-outcome
injection I-outcome

Rate I-outcome
of I-outcome

Symptomatic O
COVID-19 O
Peak O
severity O
of B-outcome
COVID-19 I-outcome
over O

Confirmed O
cases O
of O
a O
COVID-19 O

Polymerase O
chain O
reaction O

The O
rate O
of O
COVID-19 B-outcome

Incidence I-outcome
rate I-outcome
of I-outcome

Occurrence O
of O
an O
symptomatic O
or B-outcome
asymptomatic I-outcome
SARS-CoV-2 O

COVID-19 O
disease O
incidence B-outcome
Severe I-outcome
COVID-19 I-outcome
disease B-outcome
incidence I-outcome

Assess I-outcome

Health O
Care O
Workers O
absenteeism O

COVID-19 B-outcome
disease I-outcome
diagnosis O

Number O
of O
participants B-outcome
with I-outcome
symptomatic, I-outcome
lab-confirmed I-outcome
COVID-19. I-outcome

new-onset I-outcome

Microbiologic O
evidence O
of B-outcome
infection I-outcome

Number I-outcome
of I-outcome
Covid-19 I-outcome
positive I-outcome

COVID-19-free O
survival O

The O
number B-outcome
of I-outcome

positive O
serology O
or O
reverse O
transcriptase O
(RT-PCR) O
for O
COVID-19 O
up O

Reduction O
in O
the B-outcome
number O

Number O
of O
confirmed O
symptomatic O
infections O
of O
SARS-CoV-2 O
(COVID-19) O

Prevention O

Reduction O
in O
COVID-19 O
infection O
frequency O

Symptomatic O
laboratory-confirmed O
COVID-19 O
Symptomatic O
laboratory-confirmed O
VRI O

Frequency O
of O
Adverse O
Events O

Prevention O
Study: O
Measure O
the O
effect O
of O
NORS O
on O
the O
prevention O
of O
COVID-19 O

Incidence O

Incidence O
of O
hospitalization O
for O
COVID-19 O
Incidence O
of O
symptoms O
for O
COVID-19 O

To O
assess O
the O
impact O
of O
hydroxychloroquine O
and O
azithromycin O
on O
the O
prevention O

Recruitment O
Feasibility O
Recourse O
utilization O

Symptomatic O
or O
asymptomatic O
SARS-CoV-2 O
infection O

50% O
reduction O
in O

Occurrence O

Impact O

Intraoral O

Polymerase O
chain O
reaction O

incidence O
(measured O
by O

Percent O
of B-outcome
patient I-outcome

Mechanical O
ventilation B-outcome

Percentage O

World O

Composite O
outcome O
of O
death, O
need O
for O
invasive O
ventilation, O
and O

Number O
of O
sick O
days O
(SDS) O
during O
the O

Lung O
CT O
Score O

Elevation O
of O
proper O
hygiene O
behaviour O
(behavioural O
change) O

Diagnosis O

COVID-19 B-outcome
infection I-outcome

Risk I-outcome
of I-outcome

occurrence O
of O
an O
symptomatic O
or O
asymptomatic O
SARS-CoV-2 O
infection O
among O
healthcare O
workers O
(HCWs) O
An O
infection O
by O
SARS-CoV-2 O
is O
defined O

nan O

viral O

Number O

One-month O
mortality O

nan O

nan O

nan O

nan O

nan O

nan O

nan O

nan B-outcome

nan I-outcome

Improvement I-outcome
of O
COVID-19 O
disease O
status O

nan O

nan O

nan O

nan B-outcome

nan O

nan O

nan O

nan O

nan I-outcome

nan I-outcome

All-cause O
hospital O
mortality O

nan O

nan O

nan O

nan B-outcome

Disappear I-outcome
time O

nan O

nan O

nan O

nan O

nan O

nan O

Time O
to O
resolution B-outcome
of I-outcome
fever O
for O

Rate O
of O

Clinical O
outcome O

Severity O
of O
COVID-19 O

Percentage I-outcome
of I-outcome
subjects O
reporting O

Hospital O
Admission O

Survival O
rate O

Viral O
load O

Reduction O
in O
the O
incidence O
of O
patients O

SARS-CoV-2 O

The O

Rate O

changes O

Sequential O
Organ O
Failure O

Determine O
the O
number O

Mortality O

Proportion O

Change O
of O
arterial O
oxygenation O

Proportion B-outcome
of I-outcome
Participants O
Discharged O
by O
Day O

Mortality O
PaO2:FiO2 O
ratio O

Size O
of O

Fever O
to O

The O
time O
to O
oxygen O
saturation O
recovery O
to O
normal O

The O
change O
of O
pneumonia O
severity O

Time O
to O
Clinical O
recoveryTime O
to O
Clinical O
Recovery O

Time O
to O
Clinical O
Improvement O
(TTCI) O

Mean O
clinical O

Time O
to O
clinical O
recovery O

lung O
injury O
score O

the O
incidence O
of O
treatment O
failure O
in O

Oxygenation O
index O

Time O
to O
Clinical O
Improvement O
(TTCI) O

High-resolution B-outcome
computed O
tomography O
(HRCT) O
score O
Lung O
function O
including O
FVC, O

Partial O
arterial I-outcome
oxygen I-outcome
pressure O
(PaO2) I-outcome
to O
fraction O
of O
inspiration O
O2 O
(FiO2) O
ratio O
Partial O

Clinical O
improvement O
based O
on O
the O
7-point O
scale O
Lower O
Murray O
lung O
injury O
score O

Size O
of O
lesion O

Rate O
of O
composite O
adverse O

Time O
to O
Clinical O
recoveryTime O
to O
Clinical O
Recovery O
(TTCR) O

Time O
to O
complete O
remission O
of O
2019-nCoV O
infection-associated O
symptoms O

Rate O

Rate O
of O
comprehensive O
adverse O
outcome O

Rate O
of O
disease O
remission O
Time O
for O
lung B-outcome
recovery I-outcome

Rate I-outcome
of I-outcome

Incidence O
of O
COVID19 O
Disease O

Time O
to O
recovery O

Virus O
negative O
conversion O
rate O
in O
the O
first O

Ventilation-free O
days O

Clinical O
recovery O
time O

Time O

The O
virological O
clearance O
rate O
of O
throat O
swabs, O
sputum, O
or B-outcome
lower O
respiratory O
tract O
secretions O
at B-outcome
day O
3 O
The O
virological O

The O
virological O

Pneumonia O
severity O
index O
Oxygenation O

arrest O
in O
deterioration O

Improvement O
of O
clinical O
symptoms O
including O
duration O
of O
fever O
Improvement O
of O
clinical O
symptoms O

The O
incidence O
of O
composite O
adverse O
outcome O

Clinical O
recovery O
time O

Lower O

Clinical O
cure O
rate O

Disppear O
time O
of O
ground-glass O
shadow O

The O
incidence O
of O
side O
effects O

Time O
to O
negative O
NPS O

chest O
CT O
Finger O
pulse O
oxygen B-outcome
blood I-outcome
gas O

The O
lowest O
SpO2 O
during O
intubation O

hospital O
length B-outcome
of O

time O
to O
clinical O
improvement O

Length O

Lung O
function O

Time O

Fatality O
rate O

Time O

Length O
of O
hospital B-outcome
stay I-outcome

St. O
George's O
Respiratory O
Questionnaire O

Primary O
indicator O
(14 O
day O
outcome O
of O
the O
subjects, O
including: I-outcome
recovery, O
improvement, O
turning O
critical, O
death.) O
Primary O
indicator O
(lung O
CT) O

Time O

Chest O
imaging O
(CT) O

Length O
of O
stay O
Length O
of O
severe O
oxygenation O
index O
during O
treatment O
all-cause O
mortality O

2019-nCoV O

ECG O
Chest O
imaging B-outcome
Complications O
vital O

14 O
day O
outcome O
of O
the O

Number O
of O
worsening O
events O

Length O
of O
hospital O
stay O

Antipyretic O
time O

Cure O
rate O
The B-outcome
cure I-outcome
time O
The O
rate O
and O
time O
at O
which O
the O
normal O

Body O
temperature O

Length O
of O

Recovery O
time O
Ratio O
and O
time O
for O
the O
general O
type O
to B-outcome
progress I-outcome
to O
heavy B-outcome
Ratio I-outcome
and I-outcome

Relief O
of B-outcome
clinical O
symptoms O
and O
duration O

TCM O
symptom O
score O
Antifebrile O
time O
The O
time O
and O
rate O
of O
transition O
of O
new O
coronavirus O
to O
Yin O

rate O

PSI O

Self-rating O
depression O
scale, O
SDS O
Self-Rating O
Anxiety O
Scale, O

pulmonary O
function O
St O
Georges B-outcome
respiratory O
questionnaire, O
SGRQ O
Modified O
Barthel O
Index, O
MBI O

Time O

Proportion O
of O
patients O
with O
a O
lung O
injury O
score O
reduction O
of O

time O
and O
rate B-outcome
of I-outcome

The O
incidence O
of O
adverse O
outcome O

TCM B-outcome
symptoms I-outcome
efficacy O

Antipyretic O
time O

Time O
for O
body O
temperature O
recovery O
Chest O
X-ray O
absorption O

CT O
of O
lung O
CT O
and O
MRI O
of O
hip O

Clinical O
and O
laboratory O
indicators O
Viral O
load O
chest O
CT O
serum O
cell O

CURB-65 O
PSI O
score O

cure O
rate O

Rate O
of O
conversion O
to O
severe O
or O
critical O
illness O

28-day O
survival O
Inflammatory O
factor O
levels O

Duration O
of O
PCR O

vital O
signs O
(Body O
temperature, O
blood O
pressure, O
heart O
rate, O
breathing O

Time O
to O
Clinical O
recovery O

pulmonary O
function O
Novel O
coronavirus O
pneumonic O

CT O
scan O
of O
the O
lungs O
Nucleic O
acid O
detection B-outcome
of I-outcome
throat O
secretion O

Chest O
CT O
Routine O
blood O

the O
condition O
worsens O
and O
develops O
into O
severe O
or O

Chest O
CT O
scan O
Nucleic O
acid O
of O
novel O
coronavirus O
Routine O
blood O
test O
Routine O
urine O
test O

Time B-outcome
to I-outcome
leave I-outcome
ventilator O
on O
day O
28 O
after O
receiving O

Physical O
examination O

Virus O
negative O
conversion O
rate O
in B-outcome
the I-outcome
first I-outcome

Declining O
speed O
of O
Novel O
Coronavirus O
by O
PCR O
Negative O

State O
anxiety O

the O
score O
of B-outcome
Hamilton I-outcome
depression O
scale O
the O
score O

PSI O

Time O
to O
viral O
negativity B-outcome
by I-outcome
RT-PCR I-outcome
Time O

Time O
to O
conversion O
of O
2019-nCoV B-outcome
RNA I-outcome
result I-outcome
from B-outcome
RI I-outcome
sample I-outcome

Cure O
rate O
Mortality O

Patient B-outcome
survival I-outcome
rate I-outcome

virus O
nucleic O

Mortality O
in O
patients O

pneumonia B-outcome
severity B-outcome
index Seperator
(PSI) I-outcome
Incidence I-outcome
of O
new B-outcome
organ Seperator
dysfunction I-outcome

The O
novel O
coronavirus B-outcome
nucleic I-outcome
acid O
negative O
rate O

Time O
to O

The O
incidence O
of O

the O
rate O
of O
remission O

Blood O
routine O
tests, O

blood O
routine O
urine O
routines O
CRP O

Time O
to O

pulmonary O
function O
Antipyretic O

pulmonary O
function O
St O
Georges O
respiratory O
questionnaire, O
SGRQ O
Modified O
Barthel O
Index, O
MBI O
Incidence O
of O
adverse O
events O

Body O
temperature O
TCM O
syndrome O
integral O
Murray O
lung O
injury O
score O
The O
transition O
time O
of O
novel O
coronavirus O
nucleic O
acid O
MuLBSTA O
score O

pulmonary O
function O
St O
Georges O
respiratory O
questionnaire, O
SGRQ O

Antipyretic O
time O
Time O
of O
virus O
turning O
negative O

clinical O
cure O
rate O
Incidence O
of O
mechanical O
ventilation O
by O
day28 O
All-cause O

Neutrophil O

Clinical O
symptoms O
Blood O
routine O
the O
viral O
load O

CD8+ O
T O
cells O
numbers O
CD4+ O
T O
cell O
numbers O
NK O

Chest O
CT B-outcome
Whole O

pneumonia O

Release O

TCM O

Severe O

Improvement O

Time O

Rate O

Quality O

The O

Clinical O
index O

lung O
function O
ADL O

Traditional O

recovery O

Chest O

Recovery O

Time O

TTCI O

The O

Disappearance O

oxygen O

SOFA O

gut O
microbiome O
Fecal O

Clinical O

Clinical O

SARS-CoV-2 O

Coronavirus O

Time B-outcome
to I-outcome
Clinical O
recovery O
Butyrate O
in O
feces O

Recovery O

hospital O

cure O

Arterial O

Time O

the O

Psychological O

Recovery B-outcome
time I-outcome
Pneumonia I-outcome
psi O
score I-outcome

Pharynx O
swabs, O
lower O
respiratory O
tract O
samples O
(sputum/endotracheal O
aspiration/alveolar O
lavage), O
and O

PCL O
HRQL O
IPAQ O
PASE O

Post-traumatic O
stress O
disorder O
checklist O
Clinical O
prognostic O
outcome O
Il-6 O

Lung O
CT O
after O
3 O
days O
Lung O
CT O

Inhospital O
time O

temperature O
respiratory O

K-bld O
questionnaire O

The O
time O
to O

negative O
conversion O
rate O
negative O
conversion O
time O

Viral O
load O
Clinical O
features O
Inflammation O
Pulmonary O

NRS O
2002 O

Time O
to O

Temperature O
Respiratory O

Clearance O
rate O
and O
time O
of O
main O
symptoms O
(fever, O
fatigue, O
cough) O

Lung B-outcome
CT O

Inflammation B-outcome
factor O

Rate O
of O
composite O

Clinical O
symptoms B-outcome
TCM O
syndrome O
Lung O
imaging O
Time I-outcome

Clinical O
recovery O
time B-outcome
Pneumonia I-outcome

Routine O
physical O
examination O
Vital O
signs: O
breathing, O

pulmonary O
function O

temperature O
respiratory O
rate O
Blood O

viral O
negative-transforming O
time O
30-day O
cause-specific O
mortality B-outcome
co-infections I-outcome
Time B-outcome
from O
severe O

Negative O
conversion O
rate O
of O
2019-nCoV O
nucleic O
acid O

the O
relive O
of O
CRS O

COVID-19 O
nucleic O
acid O
detection O
time O
from O
positive O
to O
negative O

Length O
of O

Negative O
conversion O
rate O
of O
COVID-19 O
nucleic O
acid B-outcome
Lung O
inflammation B-outcome
absorption I-outcome
ratio O

Time O
to O

cough O

time O
to B-outcome
recovery. I-outcome

SOFA O
score O

nan O

Validity O
observation O

Time O
to O
Clinical O
Recovery, O
TTCR O

TTCI O
(Time O

The O

Clinical O
therapeutic O

Time O
to O
Clinical O
Recovery O
(TTCR) O

Chest O
imaging O
Oxygenation O
index O
Extravascular O
pulmonary O
water O

Mortality O

Sputum/nasal O
swab/pharyngeal O
swab/lower O
respiratory O

Cure O
rate I-outcome

Tempreture I-outcome
Virus O
nucleic O
acid O

Rate O
of O
composite O
advers O
outcomes: O
SPO2, O
PaO2/FiO2 O
and O
respiratory O
rate O

Real-time O
fluorescent O
RT-PCR O
detection O

The O
time B-outcome
of I-outcome
duration I-outcome
of I-outcome
COVID-19 I-outcome
nucleic O
acid O
RT-PCR O
test O

Psychological O
status O

Progression O
rate O
from O
mild O
to O
critical/severe O

fever O
clearance O

Pulmonary O
function O
6 O
minutes B-outcome
walking O
distance O
The O
Short O

PaO2 B-outcome
/ I-outcome
FiO2 I-outcome
or I-outcome
respiratory O
rate I-outcome
(without I-outcome
oxygen) O

SpO2 B-outcome
during I-outcome
intubation I-outcome
the O
total O

MRC O
breathlessness B-outcome
scale I-outcome
6MWD I-outcome

Incidence O

28 B-outcome
day I-outcome
mortality I-outcome

Clinical I-outcome
symptom O
improvement O

lasting O
time O
of O

28 O
day O
mortality O

Main O
symptom O
relief O
time B-outcome

CRP I-outcome
ESR O
PCT O
Tn O

Safety B-outcome

Clinical O

Severe B-outcome
conversion I-outcome
rate I-outcome
Oxygenation O
index O

Clinical O
symptoms O
(fever, O
weakness, O
cough) O

Clinical O
symptoms O
(fever, O
weakness, O
cough) O
recovery O
rate O
and O
recovery O
time O

the O
number O
of O

Improvement O
of O
symptoms O

Clinical O
cure O
rate O

2019-ncov-RNA O
Chest O
CT O
Routine O
blood O
test O

Average O
discharge O
time O
WBC O
ALT, O
AST, O
gama-GT, O
BUN, O
Cr, O
CK-MB O
turn O
serious/crisis O

Length O
of O
stay O
in O
ICU O
Diaphragm O
movement O

CK-MB O
CTnI O
neuron-specific O
enolase,NSE O
BUN O

Time O
to O
Clinical O
Improvement O
(TTCI) O

Serum O
amyloid O

14 O
day O
outcome O
of O
the O

HRCT O
pulmonary O
fibrosis O
score O

nan O

Cough O
Score O
Expectoration O
score O

The O
time O
for O
the O
positive O

blood B-outcome
gas I-outcome
SOFA O
score O

CRP O
IL-6 O
TNF-alpha O

nucleic O
acids O
probing O
blood B-outcome
routine I-outcome

death B-outcome
Number I-outcome
of I-outcome
failure I-outcome
organs O
Length I-outcome
of I-outcome
hospital O

Medical B-outcome
imaging I-outcome
improvement I-outcome
rate I-outcome
in O
patients O
during O
recovery O

Inpatient O
mortality O
ICU B-outcome
hospital I-outcome

Time O
to O
Clinical O
Recovery O

Time O
to O
clinical O
recovery O

chest O
computerized O
tomography O
Nucleic B-outcome
acid I-outcome

Lung O
CT O

Time B-outcome
to I-outcome

Time O
to O
Virus O
Eradication O

Recovery O
time O
Pneumonia B-outcome
psi I-outcome

Status O
of O
immune O
function O

The O
percentage O
of O
patients O
who O
convert O
to O
moderate O
one O
The O
rate O
of O

nan O

The O
time O
when O
the B-outcome
nucleic I-outcome
acid O
of O
the O
novel O
coronavirus O
turns O
negative O
Conversion O
to O
heavy/critical O
type O

Time B-outcome
and I-outcome
rate I-outcome

lasting B-outcome
time I-outcome
of I-outcome
fever O
lasting O
time O
of O
novel O

Complete O
Blood O

Endotracheal O
intubation O
rate O

The B-outcome
negative I-outcome
conversion I-outcome
rate I-outcome
and O
negative O
conversion O
time O
of O

Self-rating O
depression B-outcome
scale I-outcome
self-rating O
anxiety O
scale O
Athens O
Insomnia O
Scale O

Temperature O
returns O
to O
normal O
for O
more O
than O

IFN-gama O
TNF-alpha B-outcome
Blood I-outcome
routine O
index O
Time O
and O
rate O
of O
coronavirus O
become O
negative O
immunoglobulin O
Exacerbation O
(transfer O
to O

Time O
of B-outcome
conversion I-outcome
to O
be O
negative O
of O
novel O
coronavirus O
nucleic O
acid O

Clinical O
symptom O
improvement O
rate: O
improvement O

Ventilation-free O
days B-outcome
mortality O

Time O
of O
conversion O
to O
be O

Mortality O
rate B-outcome

Time I-outcome
to O
disease O
recovery O

Time O
to O
disease O
recovery O

Oxygen O
Inhalation O
Frequency O
Oxygen O
Intake O
Time O

Time O
to O
disease O

Time B-outcome
to O
disease O

HRCT O
score O

Pulmonary O
function O
evaluation O
Changes O

syndrome O
nucleic O
acid B-outcome
of O

Pittsburgh O
sleep O
quality O
index I-outcome
Self-rating O
anxiety B-outcome
scale I-outcome
Self-rating O

insomnia O
anxiety O
depression O
comfort I-outcome

GAD-7 O
STAI-Y B-outcome
(C) I-outcome

improvement O
or O
recovery O
of O
respiratory O
symptoms B-outcome
viral I-outcome
nucleic O
acid O
shedding O

Inflammation O

The O
biochemical O
indicators O

Quantitative O
table B-outcome
of I-outcome

nuclear O
acid O
test O

Changes O
of O
serum O
inflammatory O
factors O

Maximal O
inspiratory I-outcome
pressure O

Body O
temperature O
returns O
to O
normal O
time O
After O
the O

The O
change O
of O
TCM B-outcome
syndrome I-outcome

Incidence B-outcome
of I-outcome
COVID-19 I-outcome
pneumonia O

Improvement O
of O

Albumin O
Cellular O
immune O

PO2/FiO2 O
ROX O

COVID-19 O

SP02 O
lesions O
of O
lung O
CT O

The B-outcome
time I-outcome
required I-outcome
for I-outcome

novel B-outcome
coronavirus I-outcome
nucleic I-outcome
acid I-outcome

Viral B-outcome
nucleic I-outcome
acid I-outcome
test I-outcome

Change O
in O

Response B-outcome
to I-outcome
treatment I-outcome
Complications I-outcome

Response O
to O

Response O
to O
treatment O
Complications O

Cough O
O2 O
saturation O
Radiographic O
features O

Clinical O
response B-outcome
to O

Response O
to O
the O
treatment B-outcome
(improvement I-outcome

Clinical B-outcome
recovery I-outcome
(composite) I-outcome
within I-outcome

Clinical B-outcome
response O
Paraclinical O

Time O
from O
COVID-19 O
test O

The O
need O
for O
hospital O
admission O
or O
death, O
for O
patients O
aged B-outcome
=50 B-outcome
years B-outcome
with I-outcome
comorbidity, B-outcome
and O
aged O
=65 O
with O

expected B-outcome
value I-outcome
and I-outcome
95% I-outcome

expected O
value O
and O

Proportion B-outcome
of I-outcome
subjects I-outcome

viral O
clearance O
in O

virological B-outcome
clearance O
at O
day-6 O

time B-outcome
of I-outcome
virus O
nucleic O
acid O

Average O
score O
on O
State-Trait O
Anxiety O
Scale B-outcome
(STAI) I-outcome
average I-outcome
score B-outcome
on B-outcome
Sleep O

survival O

nan B-outcome

nan O

Side O
effects O

Change O
in O
Viral O
Load O
Change O

All-cause O
mortality O

Mortality O
rate O

Change B-outcome
in O
Viral O
Load I-outcome
Change B-outcome
in I-outcome
Immunoglobulin I-outcome
M I-outcome
COVID-19 B-outcome
antibodies B-outcome
Titers B-outcome
Change I-outcome

Duration O
of O
Viral O

Duration O
of O
viral O
shedding O
in O
days O
Time O
to O
clinical O
recovery O
(TTCR) O
in O
days O
Treatment-emergent I-outcome
adverse O

COVID-19-related O

Proportion O
of O

Clinical O

Recovery O
of O

Change O
in O

28-day O
survival O
rate O

Rate O
of O
SARS-CoV-2 O
eradication O
at B-outcome
day B-outcome
14 B-outcome
from I-outcome
study B-outcome

Composite O
of O

COVID O
Ordinal O
Outcomes O
Scale O

Composite B-outcome
of I-outcome
cumulative I-outcome
death I-outcome

Efficacy O
of O

Median O
release O

COVID O
Ordinal B-outcome
Outcomes O

Hospitalization O

Proportion O
of O
patients O
requiring O
ICU O
admission O
at O
any O
time O
within O
the O
study O
period. O

Mortality O

Change O
in O
Oxygen O
Saturation O
by O
Pulse O
Oximetry O

PO2/FiO2 O
(Safety) O
PO2/FiO2 O
(Efficacy) O
Early O

National B-outcome
Institute I-outcome
of O
Allergy O
and O
Infectious O

Viral O
clearance I-outcome
time O

Time O
to O

Mortality O
day O
10 O
Mortality O
day O
30 O
Changes O
of O
C-reactive O
protein O
day O
1 O

Evolution O
of O
acute O

Incidence O
of O

Virus O
duration O

Improvement O
in O
oxygenation O

Clear O
chest O
CT-scan O
PCR O
test O

Time O
to O
clinical O

Mortality O
at O
60days O

Improved O
clinical O
status O
Return O
to O
room O
air O

Outpatients: O

Cumulative O
incidence O
of O
composite I-outcome
outcome O
of O

Clinical O
response O
Side O

National O
Early O

Change O
from O
baseline O
score O
of O
Nutrition O
risk O
screening-2002 O
(NRS-2002) O
at O
end O

Number O
of O
participants O

RNA O

In-hospital O
mortality B-outcome

Change O
from O

interleukin-6 O
(IL-6) B-outcome
level O
after O

Clinical B-outcome
status I-outcome
of O
subject O
at O

death O

Days O

Ventilator-free O
days O

Number B-outcome
patients O
developing O

Ventilator O
Free O
Days O
Duration O

Clinical O
Status O
Assessed O
Using O
a O
7-Category O
Ordinal O

CRP O
increase O

Respiratory O
efficacy O
evaluated O
by O
the O
increase B-outcome
in O
PaO2/FiO2 O
ratio O
from O
baseline O
to O
day O
7 O
in O
the O
experimental O

ventilator O
free O
days O

In-hospital O
mortality B-outcome
Need I-outcome
for O
mechanical O

need O
of O
mechanical O
ventilation O

Clinical O
status O

Adverse B-outcome
reaction I-outcome
(AE) Seperator
and I-outcome
severe O
adverse I-outcome
reaction B-outcome
(SAE) B-outcome
Changes B-outcome
of I-outcome
lung O

Treatment O
success O

Treatment O
failure O
Intubation O
rate O

Clinical B-outcome
improvement B-outcome
Hospital B-outcome
discharge O

Composite O
primary O

The O
percentage O
of O
patients O
requiring B-outcome
transfer O
to O

Rate O
of O
recovery O
from O
positive O
to O
negative O
swaps O
Fever O
to O
normal O

Pulse O
oximetry O
level O

In-hospital O
mortality O

Time O
(in B-outcome
days) O

Mortality O
rate O
Clinical O
status O
evaluated O
in B-outcome
agreement I-outcome

Number O
of O
death O
from O
any O
cause, O
or O
the O
need O
for O
intubation O
and O
mechanical O
ventilation O

Evaluation O
of I-outcome
the I-outcome

Phase O

Mortality O
rate O
reduction O
of B-outcome
50% I-outcome
by O
day O
28 O

All-cause O
mortality O

reduction O
in O
oxygen O
and O
ventilation O
support O

Proportion O
of O
participants O
with O
normalization O
of O
fever O
and O
oxygen O
saturation O
by O
day O
14 O

Survival O
without O
needs O
of O

Time O
to O
independence O

Survival O
without O

Number O
of O
days O
alive O
and O
discharged O

Percent O
of O
subjects O

Percent O
of O
subjects O
who O
have O

Measure O
the O
safety O
of I-outcome
160ppm O

Viral O
nucleic O
acid O

Death O
or O
need O

Number O
of O
deceased O
participants O
or O

ICU O
length O
of O
stay O

SOFA O
scores O

i. O
Clinical O

Category O
Changes O
in O

Improvement O

For O
patients O

Feasibility O
of O
performing O

Recovery B-outcome
time I-outcome

Cause I-outcome
of O
death O

time B-outcome
to O

The O
proportion O
of B-outcome
patients O
requiring O
mechanical O
ventilation O
Mean O

Rates O
of O

Comparison B-outcome
of O
the O

Difference O
in O
time O
to O

Prevalence O
and O
the O

Number O
of O
participants O
with I-outcome
treatment-related B-outcome
adverse I-outcome
events B-outcome
as I-outcome
assessed B-outcome
by I-outcome

Hospitalization O

World I-outcome
Health O
Organization O
(WHO) O
ordinal I-outcome
scale B-outcome
measured O

Phase O
2: O
Cumulative O
incidence O

Percentage O

Time O
from O

Effect O
of O

The O
self-rated O

Virology B-outcome
Cure I-outcome
Rate I-outcome

To I-outcome

The O
immune O

TTCI O

Changes O
in O
clinical O
critical O
treatment O

Admission O
to O
Intensive O
Care O
Unit O

Overall O
mortality O

Rates O
of O
return O
visits O

Mortality O
Viral O

Assessment O
of O
weaning O

Treatment O
failure O
rate O

Changes O

progression O
of O

Successful O
treatment O
as O
determined O
by O
Negative O
Test O
and O
resolution O
of O

Number O
of B-outcome
mechanical O
ventilation O
days. O

Time O
to O
clinical O
worsening O

Number O
of O
cured B-outcome
patients I-outcome

The O
time-to-death O
from O
all O
causes O
The O

Time O
to O
normalize O

Hospitalization O
within O
14 O
days O
of O

Time O
to O
clinical O

Number O
of O
patients O

Decrease O
incidence O
of O

Antiviral B-outcome
Activity I-outcome
Improvement I-outcome
of I-outcome
oxygenation O

Change O
in O
respiratory O
status O

Time O
to O

Undetectable O
COVID O

The O
effect O

Time B-outcome
to O

Survival O

Viral O

first O

Time O

Need O
for O

Viral B-outcome
load I-outcome

Proportion I-outcome
of O
surviving O
patients O
without O
need O

Proportion O
of O
patients O
who O
progress O
to O
require O

Stop O
home O
isolation O
NEWS O
score O

Evaluation O
of O

Incidence O
of O
serious O
adverse O
events O

Critical O
condition O
or O
death O
IL-6 O

Clinical O
Improvement O
as O
assessed O
by O

Proportion O
of O

Proportion O
(%) O
of O
subjects O
experiencing O
deterioration O

Changes O
of O
oxygenation O
index O
(PaO2/FiO2) B-outcome
Side O

Death O

Number O
of O
antibiotic O
free B-outcome
days O

Survival O
without O
needs O
of O
intubation B-outcome
at O

Change O
of O
baseline O
total O
sequential O
organ O

Mortality O

overall B-outcome
response I-outcome
rate I-outcome
in I-outcome
reversal O
of O

A B-outcome
composite I-outcome
score I-outcome
based I-outcome

Composite O
outcome O
of B-outcome
arterial O
or O
venous O
thrombosis, O
disseminated O
intravascular O
coagulation O

Duration O
of O

Mechanical O

Total O
Hospitalization O
Total O

Changes O
in O
Glucose O
Llevels O

Percentage O

28 O
day O
all O

The O
change O
of O
viral O

Time O
to O
clinical O
improvement B-outcome
of I-outcome

Number O
of O
death O
of O
any O
cause, O
during O

Improvement B-outcome
on I-outcome
a I-outcome
7-point I-outcome

Day-28 O
mortality O

Proportion O
of O
patients B-outcome
with I-outcome
onset O
of O
severe O
acute O
respiratory O
syndrome O
(SARS) O

Not O
hospitalized O

Disease O
progression O
Time O
to O
mechanical O
ventilation O

Mortality O
rate O
at O
day O
28 O

Number O
of O
ventilator-free O
days O

Laboratory O
Result O
Clinical O
Outcome B-outcome

Proportion O
of O
"responder" O
patients B-outcome
to I-outcome
prone O
position B-outcome

Survival I-outcome
without O
needs B-outcome
of I-outcome
ventilator O
utilization O
at O
day O

Hours O
to O

The O
number O

Global O

Change O

Changes O

Changes O

Symptom O

PaCO2 O

Composite O

all-cause O
mortality O
at O
90 O

TTCI O

Self-assessment O
of O
sleep O
quality O

Hospital O
stay O

Clearance O
time O
of O

TCM B-outcome
Syndrome I-outcome
Scale I-outcome

time I-outcome
till O

Clinical B-outcome
status I-outcome
of I-outcome
subject I-outcome
at O
day O
1 O

Time O
to O
improvement O
of O
2 O
points O
in O
clinical O
status O
assessment O
from O
baseline O

All-cause O
in-hospital O

Time O
of O

Prostaglandin O
E2 O

Chest O
Imaging O
lung O

FVC O

Safety O

Electrocardiogram O
St O
George's B-outcome
Respiratory O
Questionnaire O

Ratio O
of O
PaO2/FiO2 O
P(A-a)O2 O

- O
Achieving O
one B-outcome
of I-outcome

Rate O
of O

Composite O
endpoint O
of O

Comparsa O
di O
uno O
di O

death O
from O
any O
cause O
use O
of O
intubation O
and O

determination O
of O

Time O
to O

Integration O
to O
community B-outcome
as O
measured O

Composite O
endpoint O

Time O
to O
clinical O
improvement O

The O

Dose O
adjustment I-outcome
required O

Mortality O

Proportion O
of B-outcome
participants I-outcome
alive O
and O

Composite B-outcome
outcome I-outcome
comprising O
tracheal O

All-cause O
mortality, O
subdivided B-outcome
by O
the O
severity O

Monitoring O
of O

Rate B-outcome
of O

Mean B-outcome
daily O
InFLUenza I-outcome
Patient-Reported O

time O
to O
liberation O
from O
ventilation O

Composite B-outcome
endpoint I-outcome
of: O

Proportion O
of O
participants O

Mortality O
on O
D28 O

Mean O

The O
primary O
outcome O

Mortality O
rate O
30 O
days O

Proportion O

Comparison O

30-day O

30-day I-outcome
mortality I-outcome
all I-outcome

relative B-outcome
change I-outcome
(%) I-outcome
from I-outcome

28-day B-outcome
survival I-outcome
rate I-outcome

time-to-death I-outcome

Time B-outcome
(days) I-outcome
to O

Main B-outcome
Objective: I-outcome
Evaluate O

Main O
Objective: O
To O
evaluate B-outcome
the I-outcome
efficacy I-outcome
of O
methylprednisolone B-outcome
treatment, I-outcome
added I-outcome

positive O
test O

severity B-outcome
of I-outcome
acute I-outcome
respiratory I-outcome
distress I-outcome
syndrome I-outcome
(as I-outcome
measured I-outcome

change O
in O
the B-outcome
disease I-outcome
severity I-outcome
category I-outcome
of O
COVID-19 B-outcome
after I-outcome
treatment I-outcome

Changes O
in O
time B-outcome
to I-outcome
clinical I-outcome
recovery O
(TTCR), B-outcome
Changes I-outcome
in I-outcome
clinical I-outcome

virological B-outcome
clearance O
rate O
using B-outcome
qRT-PCR I-outcome
in I-outcome

positive-to-negative O
conversion O

clinical B-outcome
recovery I-outcome
rate I-outcome

nan O

nan B-outcome

nan I-outcome

nan I-outcome

Respiratory O
function O

viral O
negative-transforming O

Safety O
of O
transfusion O

safety O
level O
of O
the O
cytokines O

Size O
of O
lesion O

Time O
course O

SARS-free O
patients O

Number B-outcome
of I-outcome
participants I-outcome
with O

Recovery B-outcome
Time I-outcome

